December 2018 ASBMT Monthly Self-Directed Learning Quiz

On behalf of the ASBMT Committee on Education, we are pleased to continue our monthly self-directed learning quiz "Basic Principles and Practices of Hematopoietic Cell Transplantation and Cell Therapy – Question and Answer Approach” for fellows in training, highlighting HCT and cell therapy topics. Answers to each question appear with evidence-based “non-exhaustive” peer-review commentary. Our aim is to provide you with a credible and freely available educational resource. Questions generated and reviewed by Syed Abutalib, MD, Mark R. Litzow, MD, and William A. Wood, MD.

Question Title

* 1. At the time of U.S. Food and Drug Administration approval, what were the overall complete responses (complete remission plus complete response with incomplete hematologic recovery) of tisagenlecleucel for the treatment of patients up to age 25 years with B-cell precursor acute lymphoblastic leukemia (ALL) that was refractory or in second or later relapse?

A. 20% - 35%

B. 40% - 55%

C. 60% - 65%

D. 70% - 95%

Question Title

* 2. At the time of U.S. Food and Drug Administration approval, what were the complete response rates of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma who had failed two or more lines of systemic therapy?

A. 30% - 35%

B. 40% - 65%

C. 70% - 80%

D. 81% - 90%

Question Title

* 3. At the time of U.S. Food and Drug Administration approval, what were the complete response rates of tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma who had failed two or more lines of systemic therapy?

A. 20% - 45%

B. 50% - 60%

C. 70% - 80%

D. 81% - 90%

Question Title

* 4. What is the recommended dose of axicabtagene ciloleucel for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy?

A. 0.2 to 5.0 x 10^6 chimeric antigen receptor-positive viable T cells/kg body-weight

B. 0.1 to 2.5 x 10^8 total chimeric antigen receptor -positive viable T cells

C. 0.6 to 6.0 x 10^8 chimeric antigen receptor -positive viable T cells

D. 2 x 10^6 chimeric antigen receptor -positive viable T cells/kg body-weight (maximum 2 x 10^8)

Question Title

* 5. Which of the following statements about axicabtagene ciloleucel and tisagenlecleucel is CORRECT?

A. Tisagenlecleucel is approved by U.S. Food and Drug Administration in the setting of relapsed/refractory primary central nervous system lymphoma

B. Axicabtagene ciloleucel is approved by U.S. Food and Drug Administration in the setting of relapsed/refractory primary mediastinal large B-cell lymphoma

C. Axicabtagene ciloleucel has 41-BB co‐stimulatory domain

D. Tisagenlecleucel has CD28 co‐stimulatory domain